130 related articles for article (PubMed ID: 18606527)
1. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
Quaak SG; van den Berg JH; Toebes M; Schumacher TN; Haanen JB; Beijnen JH; Nuijen B
Eur J Pharm Biopharm; 2008 Oct; 70(2):429-38. PubMed ID: 18606527
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.
Quaak SG; Nuijen B; Haanen JB; Beijnen JH
J Pharm Biomed Anal; 2009 Feb; 49(2):282-8. PubMed ID: 19111423
[TBL] [Abstract][Full Text] [Related]
3. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
Przybylowski M; Bartido S; Borquez-Ojeda O; Sadelain M; Rivière I
Vaccine; 2007 Jun; 25(27):5013-24. PubMed ID: 17537555
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
5. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
Pavlenko M; Leder C; Pisa P
Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
[TBL] [Abstract][Full Text] [Related]
6. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
7. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
Weide B; Garbe C; Rammensee HG; Pascolo S
Immunol Lett; 2008 Jan; 115(1):33-42. PubMed ID: 18006079
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
9. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
10. Long term stability of lyophilized plasmid DNA pDERMATT.
van der Heijden I; Beijnen JH; Nuijen B
Int J Pharm; 2013 Sep; 453(2):648-50. PubMed ID: 23792100
[TBL] [Abstract][Full Text] [Related]
11. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
13. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage.
Cai Y; Rodriguez S; Rameswaran R; Draghia-Akli R; Juba RJ; Hebel H
Vaccine; 2010 Feb; 28(8):2046-52. PubMed ID: 19896448
[TBL] [Abstract][Full Text] [Related]
14. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
15. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
Triozzi PL; Aldrich W; Allen KO; Carlisle RR; LoBuglio AF; Conry RM
J Immunother; 2005; 28(4):382-8. PubMed ID: 16000957
[TBL] [Abstract][Full Text] [Related]
18. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
[TBL] [Abstract][Full Text] [Related]
19. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.
Weide B; Carralot JP; Reese A; Scheel B; Eigentler TK; Hoerr I; Rammensee HG; Garbe C; Pascolo S
J Immunother; 2008; 31(2):180-8. PubMed ID: 18481387
[TBL] [Abstract][Full Text] [Related]
20. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
